Page 2 - ஷேனிாங் மருந்து பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SHANGHAI and GAITHERSBURG, Md., June 1, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that Dr. Ruyi He and Professor Rong Shao have been elected as members of the Company s board of directors. Dr. Ruyi He will serve on the compensation committee and Professor Shao will serve on the corporate governance committee both effective June 1, 2021. We are honored to welcome Dr. He and Professor Shao to our board, and look forward to their wealth of industry experience and breadth of relationships as we transform into a fully integrated global biopharmaceutical company. Both Dr. He and Professor Shao are leading experts in their respective fields, and their appointments will further strengthen I-Mab s next phase of growth, said Dr. Jingwu Zang, Founder, Chairman and Director of I-Mab.

National institutes of healthUnited statesHong kongSan diegoHoward university hospitalDistrict of columbiaEmilie wuRong shaoGigi fengJingwu zangJielun zhuDrug administration lawShenyang pharmaceutical universityNational institute of diabetesPrnewswire the company nasdaqChina medical university